Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download 1 Public Relations Provista Diagnostics 212
Document related concepts
no text concepts found
Transcript
PublicRelations ProvistaDiagnostics [email protected] 212-202-3170 ProvistaDiagnosticsExpandsExclusiveLicenseAgreementforBiomarkerTechnologiesDevelopedat theBiodesignInstituteatArizonaStateUniversity NewYork,NY–May27,2014–ProvistaDiagnostics,Inc.,amoleculardiagnosticscompanydeveloping andcommercializingproteomic-baseddiagnostic,prognosticandmonitoringtestsforcancersaffecting women,todayannouncedithasexpandeditsexclusivelicenseagreementforcertainbiomarkerand autoantibodytechnologiesidentifiedbyresearchersJoshuaLaBaerandKarenAndersonoftheBiodesign InstituteofArizonaStateUniversity.ThelicenseprovidesProvistawithaccesstopatents,proprietary technology,materials,processingtechniquesandprotocolsnecessaryfordetectionofcertain autoantibodiesanduseofcertainbiomarkers. ThisagreementexpandsProvista’sevaluationlicense,allowingfulluseofthesetechnologiesforfurther researchanddevelopmentofdiagnosticsproductsforearlydetectionofbreastcancer,ovariancancer andhumanpapillomavirus.Thefirstagreement,signedinOctoberof2013,enabledinitialevaluationof applicabilityforthispurpose. "Thisisanimportantnextstepinsignifyingthepotentialclinicalandmarketviabilityofourresearchand developmentfocus,"saidDr.DavidE.Reese,PresidentandChiefExecutiveOfficerofProvista.“The technologieswerediscoveredatHarvardUniversityMedicalSchoolandDana-FarberCancerInstitute andcompletedatASUBiodesignInstituteinthelaboratoriesofJoshuaLaBaer,MD,PhD.andKaren AndersonMD,PhD.TheseadvancesareimportanttoProvista’sdiagnosticsstrategy.Thecombinationof thesebiomarkerswithourproprietaryassaysisimportantinthedevelopmentofproteomictestsfor earlycancerdetection.” Biomarkers,substanceswithinthebodythatcanindicatethepresenceofadiseasepriortotheclinical manifestationofsymptoms,canhelpdetectcanceratanearlystage,whichhasbeenshownto 1 significantlyimprovetreatmentoutcomesandsurvivability.Forexample,accordingtotheAmerican CancerSociety,whenovariancancerisdiagnosedatanearlystage,thefive-yearsurvivalrateisgreater than90percent.However,fewerthanoneinfivecasesisdetectedinanearlystage,becausesymptoms aretypicallyminimalandinvasivesurgeryisrequiredfordiagnosis.Todate,noscreeningbiomarkers arerecommendedforthegeneralpopulationindetectingovariancancer. Inthecaseofbreastcancer,whiletherehavebeenadvancesindetectionandtreatment,thedisease remainsacommonanddevastatinghealthproblemthatcanbedifficulttodiagnose.Strikingalmost oneineightwomenintheU.S.,accordingtotheAmericanCancerSociety,breastcancerisfrequently notdiagnoseduntilalatestage. “Theprospectfordiagnostictoolstopinpointbiomarkersindicatingthepresenceofcancersthathave otherwisebeenundetectablepresentsamajoropportunityforimprovedclinicalcare,”saidJoshua LaBaer,directoroftheVirginiaG.PiperCenterforPersonalizedDiagnosticsattheBiodesignInstituteat ASU.“WearepleasedProvistaseesthevalueofourresearch,aswestronglybelievethatearlierdisease detectionoffersthepotentialtonotonlysavemorepatientlives,buttogreatlyreducetreatment burdensandhealthsystemcosts.” ThelicensingagreementwasbrokeredbyArizonaTechnologyEnterprises(AzTE);ASU'stechnology transferorganization.ASU,throughtheactivitiesofAzTE,isannuallyoneofthetop-performingU.S. universitiesintermsofintellectualpropertyinputs(inventionsdisclosedbyASUresearchers)and outputs(licensingdealsandstart-ups)relativetothesizeoftheuniversity'sresearchenterprise. AboutArizonaTechnologyEnterprises Establishedin2003,ArizonaTechnologyEnterprises(AzTE)isawholly-ownedsubsidiaryoftheArizona StateUniversityFoundationforANewAmericanUniversity.OverthelasttenyearsArizonaTechnology Enterpriseshassupportedthedevelopmentofmorethan70ASUspinoutcompanies.Comprising industryanduniversityveterans,AzTEbringstogetherASU'sresearchersandindustrypartnersto transformdiscoveriesintomarketableproductsandservices,takinginnovationoutofthelabandinto thecommercialmarketplace.Formoreinformation,visit:AzTE.com 2 AboutProvista ProvistaDiagnosticsisaprivatelyheldmoleculardiagnosticscompanyfocusedondevelopingand commercializinganewgenerationofproprietaryblood-basedproteomicdiagnostic,prognosticand monitoringtestsdesignedtoaddresstheunmetneedsinwomen’scancer,suchasbreastand gynecologiccancers.ProvistaDiagnostics’state-of-the-art,high-complexityclinicallaboratoryis accreditedbytheCollegeofAmericanPathologists(CAP)andwiththeClinicalLaboratoryImprovement Amendments(CLIA). AdditionalinformationaboutProvistaDiagnosticsisavailableatProvistaDx.com InformationaboutProvistaDiagnostics’clinicaltrialsisavailableatClinicalTrials.gov SafeHarborStatement Statementscontainedinthiscommunicationnotrelatingtohistoricalfactsareforward-looking statementsthatareintendedtofallwithinthesafeharborruleforsuchstatementsunderthePrivate SecuritiesLitigationReformActof1995.Theinformationcontainedintheforward-lookingstatementsis inherentlyuncertain,andProvista’sactualresultsmaydiffermateriallyduetoanumberoffactors, manyofwhicharebeyondProvista’sabilitytopredictorcontrol,includingamongothers,viabilityand effectivenessofoursalesapproachandoverallmarketingstrategies,theoutcomeofdevelopmentor regulatoryreviewofourproducts,commercialsuccessoracceptancebythemedicalcommunity, competitiveresponses,ourabilitytoraiseadditionalcapital,andtheabilitytosuccessfullyfilea registrationstatementwiththeSEC.Theseforward-lookingstatementsaresubjecttoknownand unknownrisksanduncertaintiesthatcouldcauseactualeventstodifferfromtheforward-looking statements.Provistaoperatesinahighlycompetitiveandrapidlychangingbusinessandregulatory environment,thusneworunforeseenrisksmayarise.Accordingly,investorsshouldnotplaceany relianceonforward-lookingstatementsasapredictionofactualresults.Exceptasisexpresslyrequired bythefederalsecuritieslaws,Provistaundertakesnoobligationtoupdateorreviseanyforward-looking statements,whetherasaresultofnewinformation,changedcircumstancesorfutureeventsorforany otherreason. ### 3
